Consolidative dendritic cell-based immunotherapy elicits cytotoxicity against malignant mesothelioma

American Journal of Respiratory and Critical Care Medicine

Volumn 181, Issue 12, 2010, Pages 1383-1390

  Hegmans, Joost P ^a   Veltman, Joris D ^a   Lambers, Margaretha E ^a   De Vries, I Jolanda M ^b   Figdor, Carl G ^b   Hendriks, Rudi W ^a   Hoogsteden, Henk C ^a   Lambrecht, Bart N ^a,c   Aerts, Joachim G ^a,d  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^c GHENT UNIVERSITY   (Belgium)

^d AMPHIA HOSPITAL   (Netherlands)

Author keywords

Antitumor; Clinical trial; Tumor lysate pulsed; Vaccinations

Indexed keywords

CARBOPLATIN; CISPLATIN; CYANOCOBALAMIN; DENDRITIC CELL VACCINE; FOLIC ACID; KEYHOLE LIMPET HEMOCYANIN; TUMOR ANTIGEN;

ADULT; AGED; ARTICLE; AUTOIMMUNITY; CANCER GRADING; CANCER IMMUNOTHERAPY; CELL INFILTRATION; CELL LYSATE; CELL THERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; CYTOTOXICITY; DELAYED HYPERSENSITIVITY; DENDRITIC CELL; DISEASE MARKER; DRUG SAFETY; FEVER; HUMAN; HUMAN TISSUE; IMMUNE RESPONSE; IN VITRO STUDY; IN VIVO STUDY; MALE; MALIGNANT MESOTHELIOMA; MULTIPLE CYCLE TREATMENT; PERIPHERAL BLOOD MONONUCLEAR CELL; PLEURA MESOTHELIOMA; PRIORITY JOURNAL; RASH; T LYMPHOCYTE; VACCINATION; FEASIBILITY STUDY; IMMUNOLOGY; IMMUNOTHERAPY; MESOTHELIOMA; METHODOLOGY; MIDDLE AGED; PLEURA TUMOR;

AGED; CYTOTOXICITY, IMMUNOLOGIC; DENDRITIC CELLS; FEASIBILITY STUDIES; HUMANS; IMMUNOTHERAPY; MALE; MESOTHELIOMA; MIDDLE AGED; PLEURAL NEOPLASMS;

EID: 77953257678     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.200909-1465OC     Document Type: Article

References (32)

1. Hoogsteden HC, Langerak AW, van der Kwast TH, Versnel MA, van Gelder T. Malignant pleural mesothelioma. Crit Rev Oncol Hematol 1997;25:97-126.
2. Robinson BW, Musk AW, Lake RA. Malignant mesothelioma. Lancet 2005;366:397-408.
3. Stumphius J, Meyer PB. Asbestos bodies and mesothelioma. Ann Occup Hyg 1968;11:283-293.
4. Burdorf A, Dahhan M, Swuste P. Occupational characteristics of cases with asbestos-related diseases in the netherlands. Ann Occup Hyg 2003;47:485-492.
5. Bianchi C, Bianchi T. Malignant mesothelioma: global incidence and relationship with asbestos. Ind Health 2007;45:379-387. (Pubitemid 47217199)
6. Vogelzang NJ. Standard therapy for the treatment of malignant pleural mesothelioma. Lung Cancer 2005;50S1:S23-S24.
7. Banchereau J, Palucka AK. Dendritic cells as therapeutic vaccines against cancer. Nat Rev Immunol 2005;5:296-306.
8. Steinman RM, Dhodapkar M. Active immunization against cancer with dendritic cells: the near future. Int J Cancer 2001;94:459-473. (Pubitemid 32979535)
9. Hegmans JP, Hemmes A, Aerts JG, Hoogsteden HC, Lambrecht BN. Immunotherapy of murine malignant mesothelioma using tumor lysate-pulsed dendritic cells. Am J Respir Crit Care Med 2005;171:1168-1177.
10. Cranmer LD, Trevor KT, Hersh EM. Clinical applications of dendritic cell vaccination in the treatment of cancer. Cancer Immunol Immunother 2004;53:275-306.
11. de Vries IJ, Adema GJ, Punt CJ, Figdor CG. Phenotypical and functional characterization of clinical-grade dendritic cells. Methods Mol Med 2005;109:113-126.
12. Berger TG, Strasser E, Smith R, Carste C, Schuler-Thurner B, Kaempgen E, Schuler G. Efficient elutriation of monocytes within a closed system (elutra) for clinical-scale generation of dendritic cells. J Immunol Methods 2005;298:61-72.
13. Verdijk P, Aarntzen EH, Lesterhuis WJ, Boullart AC, Kok E, van Rossum MM, Strijk S, Eijckeler F, Bonenkamp JJ, Jacobs JF, et al. Limited amounts of dendritic cells migrate into the T-cell area of lymph nodes but have high immune activating potential in melanoma patients. Clin Cancer Res 2009;15:2531-2540.
14. Dhodapkar MV, Steinman RM, Krasovsky J, Munz C, Bhardwaj N. Antigen-specific inhibition of effector T cell function in humans after injection of immature dendritic cells. J Exp Med 2001;193:233-238.
15. Jonuleit H, Giesecke-Tuettenberg A, Tuting T, Thurner-Schuler B, Stuge TB, Paragnik L, Kandemir A, Lee PP, Schuler G, Knop J, et al. A comparison of two types of dendritic cell as adjuvants for the induction of melanoma-specific T-cell responses in humans following intranodal injection. Int J Cancer 2001;93:243-251.
16. Gregoire M, Ligeza-Poisson C, Juge-Morineau N, Spisek R. Anti-cancer therapy using dendritic cells and apoptotic tumour cells: pre-clinical data in human mesothelioma and acute myeloid leukaemia. Vaccine 2003;21:791-794.
17. Nestle FO, Alijagic S, Gilliet M, Sun Y, Grabbe S, Dummer R, Burg G, Schadendorf D. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med 1998;4:328-332.
18. Gabrilovich DI. Combination of chemotherapy and immunotherapy for cancer: a paradigm revisited. Lancet Oncol 2007;8:2-3.
19. McCoy MJ, Nowak AK, Lake RA. Chemoimmunotherapy: an emerging strategy for the treatment of malignant mesothelioma. Tissue Antigens 2009;74:1-10.
20. Ampollini L, Soltermann A, Felley-Bosco E, Lardinois D, Arni S, Speck RF, Weder W, Opitz I. Immuno-chemotherapy reduces recurrence of malignant pleural mesothelioma: an experimental setting. Eur J Cardiothorac Surg 2009;35:457-462.
21. Nowak A. Chemoimmunotherapy in mesothelioma. 9th International Conference of the International Mesothelioma Interest Group, Amsterdam, The Netherlands, September 25-27, 2008 [abstract 189].
22. van Klaveren RJ, Aerts JG, de Bruin H, Giaccone G, Manegold C, van Meerbeeck JP. Inadequacy of the recist criteria for response evaluation in patients with malignant pleural mesothelioma. Lung Cancer 2004;43:63-69.
23. Holtl L, Rieser C, Papesh C, Ramoner R, Herold M, Klocker H, Radmayr C, Stenzl A, Bartsch G, Thurnher M. Cellular and humoral immune responses in patients with metastatic renal cell carcinoma after vaccination with antigen pulsed dendritic cells. J Urol 1999;161:777-782. (Pubitemid 29422365)
24. +T-cell priming and help to peptide-specific cytotoxic T-cell response, in view of potential use in cancer vaccines. Vaccine 2003;21:869-876.
25. Aarntzen EH, Figdor CG, Adema GJ, Punt CJ, de Vries IJ. Dendritic cell vaccination and immune monitoring. Cancer Immunol Immunother 2008;57:1559-1568.
26. De Vries IJ, Bernsen MR, van Geloof WL, Scharenborg NM, Lesterhuis WJ, Rombout PD, Van Muijen GN, Figdor CG, Punt CJ, Ruiter DJ, et al. In situ detection of antigen-specific T cells in cryo-sections using MHC class I tetramers after dendritic cell vaccination of melanoma patients. Cancer Immunol Immunother 2007;56:1667-1676.
27. de Vries IJ, Bernsen MR, Lesterhuis WJ, Scharenborg NM, Strijk SP, Gerritsen MJ, Ruiter DJ, Figdor CG, Punt CJ, Adema GJ. Immunomonitoring tumor-specific T cells in delayed-type hypersensitivity skin biopsies after dendritic cell vaccination correlates with clinical outcome. J Clin Oncol 2005;23:5779-5787.
28. Hegmans JP, Hemmes A, Hammad H, Boon L, Hoogsteden HC, Lambrecht BN. Mesothelioma environment comprises cytokines and T-regulatory cells that suppress immune responses. Eur Respir J 2006;27:1086-1095.
29. Almand B, Clark JI, Nikitina E, van Beynen J, English NR, Knight SC, Carbone DP, Gabrilovich DI. Increased production of immature myeloid cells in cancer patients: a mechanism of immunosuppression in cancer. J Immunol 2001;166:678-689.
30. Gabrilovich D, Pisarev V. Tumor escape from immune response: mechanisms and targets of activity. Curr Drug Targets 2003;4:525-536.
31. Rabinovich GA, Gabrilovich D, Sotomayor EM. Immunosuppressive strategies that are mediated by tumor cells. Annu Rev Immunol 2007;25:267-296.
32. Nagaraj S, Gabrilovich DI. Tumor escape mechanism governed by myeloid-derived suppressor cells. Cancer Res 2008;68:2561-2563. (Pubitemid 351556251)